Paper Details

  1. Home
  2. Paper Details

Adverse drug reactions to integrase strand transfer inhibitors.

Author: AkagiLinda, BarriosRolando, GuillemiSilvia, LepikKatherine J, LimaViviane Dias, MontanerJulio S G, ToyJunine, UlloaAna C, WangLu, YipBenita

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Integrase strand transfer inhibitors (INSTIs) were generally well tolerated, but elvitegravir-cobicistat was associated with a higher rate of gastrointestinal and general adverse drug reactions compared to dolutegravir.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To describe and compare integrase strand transfer inhibitor (INSTI) adverse drug reactions (ADRs) for raltegravir, elvitegravir-cobicistat, and dolutegravir. DESIGN: Population-based, retrospective cohort. METHODS: Antiretroviral-experienced and naive persons at least 19 years old were...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/QAD.0000000000001781

データ提供：米国国立医学図書館（NLM）

Integrase Strand Transfer Inhibitors: A Comparative Analysis of Adverse Drug Reactions

Integrase strand transfer inhibitors (INSTIs) are an important class of antiretroviral medications used to treat HIV infection. This research examines the adverse drug reactions (ADRs) associated with three INSTIs: raltegravir, elvitegravir-cobicistat, and dolutegravir. The study aims to compare the ADR profiles of these medications and identify potential differences in their tolerability.

Navigating the Desert of Antiretroviral Therapy

The research analyzes a population-based cohort of individuals receiving INSTIs in British Columbia, Canada. The primary outcome was ADR-related INSTI discontinuation. The study found that elvitegravir-cobicistat had a significantly higher ADR rate compared to dolutegravir. Elvitegravir-cobicistat-treated individuals experienced a greater proportion of gastrointestinal and general (fatigue, malaise) ADRs, while dolutegravir was associated with more frequent neuropsychiatric ADRs. However, there was no apparent relationship between experiencing an ADR to one INSTI and subsequent intolerance to another.

Choosing the Right Path in the Desert: Individualizing Antiretroviral Therapy

Antiretroviral therapy for HIV infection can be a long and challenging journey. This research underscores the importance of individualizing therapy, considering the potential side effect profiles of different INSTIs. By understanding these differences, healthcare providers can make more informed decisions to optimize treatment outcomes.

Dr. Camel's Conclusion

Finding the right antiretroviral therapy for HIV is like choosing the right camel for a long desert trek. Each medication has its own unique characteristics and potential side effects. This research helps illuminate the potential risks and benefits associated with different INSTIs, allowing us to make more informed decisions and navigate the desert of HIV treatment with greater confidence.
Date :
  1. Date Completed 2019-09-19
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

29424784

DOI: Digital Object Identifier

10.1097/QAD.0000000000001781

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.